Cover
Cover - shares | 9 Months Ended | |
Dec. 31, 2022 | Jan. 24, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Dec. 31, 2022 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --03-31 | |
Entity File Number | 000-53230 | |
Entity Registrant Name | REGENEREX PHARMA, INC. | |
Entity Central Index Key | 0001357878 | |
Entity Tax Identification Number | 98-0479983 | |
Entity Incorporation, State or Country Code | NV | |
Entity Address, Address Line One | 5348 Vegas Drive #177 | |
Entity Address, City or Town | Las Vegas | |
Entity Address, State or Province | NV | |
Entity Address, Postal Zip Code | 89108 | |
City Area Code | (702) | |
Local Phone Number | 273-3772 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Elected Not To Use the Extended Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 277,112,660 |
BALANCE SHEETS (UNAUDITED)
BALANCE SHEETS (UNAUDITED) - USD ($) | Dec. 31, 2022 | Mar. 31, 2022 |
Current Assets | ||
Cash and equivalents | $ 1,203 | $ 2,640 |
Prepaid expenses | 2,500 | 5,256 |
Total Current Assets | 3,703 | 7,896 |
Website, net of accumulated amortization of $25,690 and $23,174, respectively | 4,910 | 7,426 |
Computer equipment, net of accumulated amortization of $82 and $0, respectively | 1,316 | |
Total Assets | 9,929 | 15,322 |
Current Liabilities | ||
Accounts payable | 66,125 | 63,027 |
Related party advances | 131,887 | 131,687 |
Accrued compensation | 221,192 | 221,192 |
Other accrued liabilities | 118,301 | 91,667 |
Current portion of notes payable to shareholder | 337,369 | 152,880 |
Total Current Liabilities | 874,874 | 660,453 |
Notes payable to shareholder, net of current portion | 173,712 | 340,486 |
Notes payable to related parties | 38,000 | |
Total Liabilities | 1,086,586 | 1,000,939 |
Stockholders’ Deficit | ||
Common stock: $0.001 par value: 675,000,000 shares authorized: 277,112,660 issued and outstanding at December 31, 2022 and March 31, 2022 | 277,113 | 277,113 |
Additional paid-in capital | 671,963 | 671,963 |
Accumulated deficit | (2,025,733) | (1,934,693) |
Total Stockholders’ Deficit | (1,076,657) | (985,617) |
Total Liabilities and Stockholders’ Deficit | $ 9,929 | $ 15,322 |
BALANCE SHEETS (UNAUDITED) (Par
BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) | Dec. 31, 2022 | Mar. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Finite-Lived Intangible Assets, Accumulated Amortization | $ 25,690 | $ 23,174 |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $ 82 | $ 0 |
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 675,000,000 | 675,000,000 |
Common Stock, Shares, Issued | 277,112,660 | 277,112,660 |
Common Stock, Shares, Outstanding | 277,112,660 | 277,112,660 |
STATEMENTS OF OPERATIONS (UNAUD
STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | |
Operating Expenses | ||||
General and administrative | $ 28,802 | $ 61,975 | $ 67,592 | $ 94,737 |
Sales and marketing | 300 | 300 | ||
Total Operating Expenses | 29,102 | 61,975 | 67,892 | 94,737 |
Operating Loss | (29,102) | (61,975) | (67,892) | (94,737) |
Other Income (Expense) | ||||
Interest expense | (17,241) | (14,548) | (49,365) | (44,130) |
Foreign currency gain (loss) | (3,057) | (1,889) | 26,217 | 483 |
Total Other Income (Expense) | (20,298) | (16,437) | (23,148) | (43,647) |
Loss from Continuing Operations | (49,400) | (78,412) | (91,040) | (138,384) |
Loss from Discontinued Operations | (1,022) | (8,758) | ||
Net Loss | $ (49,400) | $ (79,434) | $ (91,040) | $ (147,142) |
Basic and Diluted Loss per Common Share | $ 0 | $ 0 | $ 0 | $ 0 |
Weighted Average Number of Common Shares Outstanding | 227,112,660 | 203,743,095 | 277,112,660 | 152,749,024 |
STATEMENTS OF CASH FLOWS (UNAUD
STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) | 9 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Cash Flows from Operating Activities: | ||
Net loss | $ (91,040) | $ (147,142) |
Loss from discontinued operations | 8,758 | |
Adjustments to reconcile net loss to cash flows used in operating activities: | ||
Depreciation | 2,598 | 2,329 |
Foreign currency adjustments | (26,217) | (483) |
Stock-based compensation | 45,000 | |
Changes in operating assets and liabilities: | ||
Prepaid expenses | 2,756 | 1,213 |
Accounts payable and accrued liabilities | 38,763 | 36,033 |
Net cash used in continuing operating activities | (73,140) | (54,292) |
Net cash used in discontinued operating activities | (8,758) | |
Net cash used in operating activities | (73,140) | (63,050) |
Cash Flows from Investing Activities: | ||
Website | (8,600) | |
Computer equipment | (1,398) | |
Net cash used in investing activities | (1,398) | (8,600) |
Cash Flows from Financing Activities: | ||
Related party advances | 200 | 455 |
Proceeds from notes payable to shareholder | 34,901 | 67,082 |
Proceeds from notes payable to related parties | 40,500 | |
Partial repayment of note payable to related parties | (2,500) | |
Net cash provided by financing activities | 73,101 | 67,537 |
Decrease in cash and equivalents | (1,437) | (4,113) |
Cash and cash equivalents, beginning of period | 2,640 | 6,902 |
Cash and cash equivalents, end of period | 1,203 | 2,789 |
Supplemental Cash Flow Information – Cash Paid For: | ||
Income Taxes | ||
Interest | ||
Non-Cash Investing and Financing Activities: | ||
Accrued interest converted into note payable to shareholder | 7,211 | 27,254 |
Shares issued for the acquisition of intellectual property | $ 150,000 |
STATEMENTS OF STOCKHOLDERS' DEF
STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Beginning balance, value at Mar. 31, 2021 | $ 127,113 | $ 776,963 | $ (1,739,102) | $ (835,026) |
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2021 | 127,112,660 | |||
Net Loss | (67,708) | (67,708) | ||
Ending balance, value at Sep. 30, 2021 | $ 127,113 | 776,963 | (1,806,810) | (902,734) |
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2021 | 127,112,660 | |||
Beginning balance, value at Mar. 31, 2021 | $ 127,113 | 776,963 | (1,739,102) | (835,026) |
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2021 | 127,112,660 | |||
Net Loss | (147,142) | |||
Ending balance, value at Dec. 31, 2021 | $ 277,113 | 671,963 | (1,886,244) | (937,168) |
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2021 | 277,112,660 | |||
Beginning balance, value at Sep. 30, 2021 | $ 127,113 | 776,963 | (1,806,810) | (902,734) |
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2021 | 127,112,660 | |||
Net Loss | $ (79,434) | $ (79,434) | ||
Common stock issued for purchase of intellectual property | 150,000 | (150,000) | ||
Stock Issued During Period, Shares, Purchase of Assets | 150,000,000 | |||
Stock-based compensation | $ 45,000 | $ 45,000 | ||
Ending balance, value at Dec. 31, 2021 | $ 277,113 | 671,963 | (1,886,244) | (937,168) |
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2021 | 277,112,660 | |||
Beginning balance, value at Mar. 31, 2022 | $ 277,113 | 671,963 | (1,934,693) | $ (985,617) |
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2022 | 277,112,660 | 277,112,660 | ||
Net Loss | (41,640) | $ (41,640) | ||
Ending balance, value at Sep. 30, 2022 | $ 277,113 | 671,963 | (1,976,333) | (1,027,257) |
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2022 | 277,112,660 | |||
Beginning balance, value at Mar. 31, 2022 | $ 277,113 | 671,963 | (1,934,693) | $ (985,617) |
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2022 | 277,112,660 | 277,112,660 | ||
Net Loss | $ (91,040) | |||
Ending balance, value at Dec. 31, 2022 | $ 277,113 | 671,963 | (2,025,733) | $ (1,076,657) |
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2022 | 277,112,660 | 277,112,660 | ||
Beginning balance, value at Sep. 30, 2022 | $ 277,113 | 671,963 | (1,976,333) | $ (1,027,257) |
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2022 | 277,112,660 | |||
Net Loss | (49,400) | (49,400) | ||
Ending balance, value at Dec. 31, 2022 | $ 277,113 | $ 671,963 | $ (2,025,733) | $ (1,076,657) |
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2022 | 277,112,660 | 277,112,660 |
NATURE OF OPERATIONS
NATURE OF OPERATIONS | 9 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
NATURE OF OPERATIONS | NOTE 1 – NATURE OF OPERATIONS Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005. The Company’s business was to develop and market proprietary skincare products that was to be sold online. The majority of manufacturing, distribution, marketing, and sales operations was outsourced. The Company’s attempt over the past four years to build a business that marketed skincare products online has not come to fruition, so management decided to change the business focus and look for other opportunities. On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15 th Management has decided to focus on this new business development. The financial results for periods prior to the abandonment of the previous business line have been reflected in the accompanying statement of operations as discontinued operations as this change represented a strategic shift in our business that had a major effect on our operations and financial results. Risks and Uncertainties Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows. The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors. The wound care healing space is well suited for Home Care service providers that are funded by the US Government. The majority of manufacturing and distribution will be outsourced. However, strategic planning and development will be performed internally by the Company. |
BASIS OF PRESENTATION OF INTERI
BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS | 9 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS | NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended December 31, 2022, are not necessarily indicative of the results that may be expected for the year ending March 31, 2023. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2022, have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2022, included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. |
GOING CONCERN
GOING CONCERN | 9 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
GOING CONCERN | NOTE 3 – GOING CONCERN These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2022, it had excess liabilities over assets of $1,076,657. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company requires significant cash to launch its business and reduce its payable. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern. |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
SIGNIFICANT ACCOUNTING POLICIES | NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government. The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. Earnings per Share Earnings per share is reported in accordance with FASB Topic 260 “ Earnings per Share December 31 , 2022, and 2021, the Company does not have any common share equivalents outstanding. Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2022 and 2021 was $723 and $2,516 and $1,016 and $2,329, respectively. Computer Equipment Expenditures related to the maintenance of the Company’s computer equipment are expensed as incurred. Purchase of computer equipment with cost over $500 are capitalized and amortized over the computer’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2022, and 2021 was $82 and $82 and $0 and $0 respectively. Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 9 Months Ended |
Dec. 31, 2022 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | NOTE 5 – RELATED PARTY TRANSACTIONS The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and Secretary/Treasurer (see note 6). Related Party Advances During the nine-month period ended December 31, 2022, the Company’s Chief Financial Officer (“CFO”) and the Company’s Chief Executive Officer (“CEO”) advanced the Company monies for operating expenses in the amount of $200. The related party advances totaled $131,887 and $131,687 as of December 31, 2022, and March 31, 2022, respectively. The related party advances accrue interest at ten (10) percent per annum. Interest expense was $9,922 and $9,879 during the nine-month periods ended December 31, 2022, and 2021, respectively. Notes Payable to Related Parties On July 29, 2022, the Company’s Chief Financial Officer (“CFO”) and the Company’s Chief Executive Officer (“CEO”) were issued a promissory note in the principal amount of $7,500 for monies advanced for operating expenses. November 13, 2022, a partial repayment of $2,500 was made by the Company. The balance outstanding on December 31, 2022, is $5,000 and accrues interest at ten (10) percent per annum with repayment due no later than July 29, 2024. On November 4, 2022, an additional promissory note was issued to the CFO and the CEO in the amount of $33,000 with repayment due no later than November 4, 2024. Interest expense was $890 and $0 during the nine-month periods ended December 31, 2022, and 2021, respectively. Note Payables to Shareholders As at December 31, 2022 and March 31, 2022, the Company had various promissory notes with total outstanding principal balances of $511,081 and $493,366, respectively, due to a shareholder of the Company. These notes are unsecured, bear interest at 10% per annum, and have maturity dates ranging from January 4, 2023, to December 30, 2024. During the nine months ended December 31, 2022, notes with principal amounts totaling approximately $35,000 ($46,500 Canadian Funds) that came due during the period were reissued in the total principal amount of approximately $46,000 ($55,800 Canadian Funds) which included the principal amount plus accrued interest of approximately $7,000 ($9,300 Canadian Funds). During the nine months ended December 31, 2022, a note with principal amount of $1,074 that came due November 22, 2022, was reissued in the principal amount of $1,289 which included the principal amount plus accrued interest of $215. The reissued notes are unsecured, bear interest at 10% per annum, and have revised maturity dates ranging from May 20, 2024, to December 30, 2024. During the nine-month period ended December 31, 2022, a shareholder was issued additional three (3) promissory notes totaling $34,901. These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due twenty-four (24) months after the date of issue. Total accrued interest on notes payable to shareholder and related parties and related party advances was $116,901 and $74,748 as of December 31, 2022, and March 31, 2022, respectively, which is included in other accrued liabilities. |
INTANGIBLE ASSETS AND INTELLECT
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY | 9 Months Ended |
Dec. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY | NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months. The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. The Technology Platforms include but are not limited to: A. B. C. D. E. F. G. H. I. J. K. Products: 1. 2. 3. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 7 – COMMITMENTS AND CONTINGENCIES The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers. See Note 6 for discussion of the $10,000,000 in contingent consideration to be paid in connection with the November 15, 2021 Asset Purchase Agreement. To date, no amounts have been payable under this agreement. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Dec. 31, 2022 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | NOTE 8 – SUBSEQUENT EVENTS On January 4, 2023, one note to a shareholder that was originally due on January 4, 2023, with a principal amount of approximately $400 ($500 Canadian Funds) was reissued in the principal amount of approximately $450 ($600 Canadian Funds) which included the original principal amount plus interest accrued as at January 4, 2023 in the amount of approximately $80 ($100 Canadian Funds). Repayment of the note is due no later than January 4, 2025. On January 5, 2023, one note to a shareholder that was originally due on January 5, 2023, with a principal amount of approximately $400 ($500 Canadian Funds) was reissued in the principal amount of approximately $450 ($600 Canadian Funds) which included the original principal amount plus interest accrued as at January 5, 2023 in the amount of approximately $80 ($100 Canadian Funds). Repayment of the note is due no later than January 5, 2025. On January 11, 2023, one note to a shareholder that was originally due on January 5, 2023, with a principal amount of approximately $800 ($1,000 Canadian Funds) was reissued in the principal amount of approximately $900 ($1,200 Canadian Funds) which included the original principal amount plus interest accrued as at January 11, 2023 in the amount of approximately $150 ($200 Canadian Funds). Repayment of the note is due no later than January 11, 2025. |
SIGNIFICANT ACCOUNTING POLICI_2
SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Revenue Recognition | Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government. The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. |
Earnings per Share | Earnings per Share Earnings per share is reported in accordance with FASB Topic 260 “ Earnings per Share December 31 , 2022, and 2021, the Company does not have any common share equivalents outstanding. |
Website | Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2022 and 2021 was $723 and $2,516 and $1,016 and $2,329, respectively. |
Computer Equipment | Computer Equipment Expenditures related to the maintenance of the Company’s computer equipment are expensed as incurred. Purchase of computer equipment with cost over $500 are capitalized and amortized over the computer’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2022, and 2021 was $82 and $82 and $0 and $0 respectively. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company. |
NATURE OF OPERATIONS (Details N
NATURE OF OPERATIONS (Details Narrative) - USD ($) | 9 Months Ended | |
Dec. 31, 2022 | Nov. 15, 2021 | |
Entity Incorporation, Date of Incorporation | Nov. 18, 2005 | |
Asset Acquisition, Contingent Consideration, Liability | $ 10,000,000 | |
Purchase Intellectual Property [Member] | ||
Shares, Issued | 150,000,000 |
SIGNIFICANT ACCOUNTING POLICI_3
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | ||||
Amortization of Intangible Assets | $ 723 | $ 1,016 | $ 2,516 | $ 2,329 |
Other Depreciation and Amortization | $ 82 | $ 0 | $ 82 | $ 0 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||||
Dec. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Nov. 04, 2022 | Jul. 29, 2022 | Mar. 31, 2022 | |
Related Party Transaction [Line Items] | ||||||
Due to Related Parties, Current | $ 131,887 | $ 131,887 | $ 131,687 | |||
Interest Expense, Related Party | 9,922 | $ 9,879 | ||||
Repayments of Secured Debt | $ 2,500 | |||||
Debt Instrument, Maturity Date Range, Start | Jan. 04, 2023 | |||||
Debt Instrument, Maturity Date Range, End | Dec. 30, 2024 | |||||
Interest Costs Incurred | $ 7,000 | |||||
Accounts Payable, Interest-Bearing | $ 116,901 | $ 116,901 | 74,748 | |||
July 292022 Note [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Debt Instrument, Face Amount | $ 7,500 | |||||
Long-Term Debt, Gross | $ 5,000 | |||||
Debt Instrument, Maturity Date | Jul. 29, 2024 | |||||
Nov 42022 Note [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Long-Term Debt, Gross | $ 33,000 | |||||
Debt Instrument, Maturity Date | Nov. 04, 2024 | |||||
Note Payable To Related Parties [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Interest Expense, Related Party | $ 890 | $ 0 | ||||
A Note [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Debt Instrument, Repurchased Face Amount | $ 1,074 | 1,074 | ||||
Debt Instrument, Repurchase Amount | $ 1,289 | 1,289 | ||||
Interest Costs Incurred | $ 215 | |||||
Reissued Notes [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Debt Instrument, Maturity Date Range, Start | May 20, 2024 | |||||
Promissory Notes 2022 [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | 10% | ||||
Debt Instrument, Description | a shareholder was issued additional three (3) promissory notes totaling $34,901 | |||||
Chief Financial Officer [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Due to Related Parties, Current | $ 200 | $ 200 | ||||
Note Payable To Shareholder [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Long-Term Debt, Fair Value | $ 511,081 | $ 511,081 | $ 493,366 | |||
Debt Instrument, Interest Rate, Stated Percentage | 10% | 10% | ||||
Debt Instrument, Repurchased Face Amount | $ 35,000 | $ 35,000 | ||||
Debt Instrument, Repurchase Amount | $ 46,000 | $ 46,000 | ||||
Debt, Weighted Average Interest Rate | 10% | 10% | ||||
Note Payable To Shareholder Reissued Debt [Member] | ||||||
Related Party Transaction [Line Items] | ||||||
Debt Instrument, Maturity Date Range, End | Dec. 30, 2024 |
INTANGIBLE ASSETS AND INTELLE_2
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative) | 1 Months Ended |
Nov. 15, 2021 shares | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 150,000,000 |
Business Combination, Contingent Consideration Arrangements, Description | up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) | 9 Months Ended |
Dec. 31, 2022 USD ($) | |
Short-Term Debt [Line Items] | |
Interest Costs Incurred | $ 7,000 |
Subsequent Event Note 1 [Member] | |
Short-Term Debt [Line Items] | |
Debt Instrument, Repurchase Date | Jan. 04, 2023 |
Debt Instrument, Repurchased Face Amount | $ 400 |
Debt Instrument, Repurchase Amount | 450 |
Interest Costs Incurred | $ 80 |
Debt Instrument, Maturity Date, Description | Repayment of the note is due no later than January 4, 2025 |
Subsequent Event Note 2 [Member] | |
Short-Term Debt [Line Items] | |
Debt Instrument, Repurchase Date | Jan. 05, 2023 |
Debt Instrument, Repurchased Face Amount | $ 400 |
Debt Instrument, Repurchase Amount | 450 |
Interest Costs Incurred | $ 80 |
Debt Instrument, Maturity Date, Description | Repayment of the note is due no later than January 5, 2025 |
Subsequent Event Note 3 [Member] | |
Short-Term Debt [Line Items] | |
Debt Instrument, Repurchase Date | Jan. 11, 2023 |
Debt Instrument, Repurchased Face Amount | $ 800 |
Debt Instrument, Repurchase Amount | 900 |
Interest Costs Incurred | $ 150 |
Debt Instrument, Maturity Date, Description | Repayment of the note is due no later than January 11, 2025 |
Uncategorized Items - ixform10q
Label | Element | Value |
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture | us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation |